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Ice-recrystallization inhibiting polymers protect
proteins against freeze-stress and enable
glycerol-free cryostorage†
Daniel E. Mitchell,‡a Alice E. R. Fayter, a Robert C. Deller, a
Muhammad Hasan, a Jose Gutierrez-Marcosb and Matthew I. Gibson *ac
Proteins are ubiquitous in molecular biotechnology, biotechnology
and as therapeutics, but there are significant challenges in their
storage and distribution, with freezing often required. This is tradi-
tionally achieved by the addition of cryoprotective agents such as
glycerol (or trehalose) or covalent modification of mutated proteins
with cryoprotectants. Here, ice recrystallization inhibiting polymers,
inspired by antifreeze proteins, are used synergistically with poly-
(ethylene glycol) as an alternative to glycerol. The primary mecha-
nism of action appears to be preventing irreversible aggregation
due to ice growth. The polymer formulation is successfully used to
cryopreserve a range of important proteins including insulin, Taq
DNA polymerase and an IgG antibody. The polymers do not require
covalent conjugation, nor modification of the protein and are already
used in a wide range of biomedical applications, which will facilitate
translation to a range of biologics.
Introduction
Proteins are ubiquitous as laboratory reagents, biocatalysts,
medicines and as food supplements. For example, in the 1980’s
insulin became the first protein therapeutic, and now 4100 are
approved in the European Union and the USA.1,2 Antibody
therapies in particular have grown and are now used for treat-
ment of cancer3 and inflammatory diseases,4 and are the fastest
growing class of therapeutics.5 A major challenge, however, is the
limited storage lifetime of proteins, with degradation being a
major issue.6,7 Environmental stresses such as temperature,
sunlight and dehydration are all crucial deactivation factors
that may aﬀect the chemical and physical stability of proteins
which along with irreversible aggregation result in inactivated
proteins.2,8 Current solutions to this challenge include lyophi-
lization or direct freezing in solution with the addition of large
concentrations of osmolytes that make unfolding thermo-
dynamically less favourable,9 though more recently spray drying
and vacuum foam drying have also been introduced.10,11 Whilst
these methods are successful, there are post-thaw issues asso-
ciated with the compatibility of high concentrations of osmolytes
used (e.g. 10–20% glycerol). This can include sample viscosity or
toxicity,12 interference with colorimetric assays, affecting protein–
protein interactions or subsequent issues relating to cytotoxicity
for studies into protein–cell interactions.13–15 Hence, direct
therapeutic injection or use in biochemical assays may often
necessitate an additional purification/dilution step. Tibbitt
et al. have shown that the reversible encapsulation of proteins
into photo-reversible hydrogel networks protects against thermal
stress by preventing aggregation,16 and encapsulation in zwitter-
ionic gels has provided in vivo stability.17 Trehalose has emerged
as an excellent stabilizer/osmolyte and is widely used as a
cryoprotectant.9,18 Maynard and co-workers have developed
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The current method used in biochemical, molecular biology, protein
engineering and therapeutic labs for freezing proteins is often based
on adding organic solvents to modulate ice formation and stabilise the
proteins. Our work takes a disruptive approach, using antifreeze-protein
mimetic polymers, which are extremely potent inhibitors of ice growth, to
enable protein cryostorage and eliminate the need for organic solvents
whilst recovering active protein. In recent years covalent polymer/protein
conjugates have been successfully used to freeze proteins, but this can be
complex, reduce protein function and crucially generates a new molecular
entity which must be tested. In our unique approach, we identified that
irreversible protein aggregation due to ice crystal growth is a major cause
of cryo-damage and that if we prevent this, the proteins retain activity.
We have formulated polymer additives which modulate ice growth and
enable quantitative recovery of a range of important proteins without
needing conjugation. This work shows that biomimetic materials
chemistry can be applied to a real clinical problem to generate unique
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trehalose polymers, which when covalently conjugated to enzymes
can protect them from heat and cold shock. Intriguingly, only a
single polymer per protein is required, thus demonstrating the
potential use of new polymeric compounds as excipients.19,20
However, the conjugation process can reduce activity relative to
free protein and depending on the protein site-specific mutations
may be necessary.21,22 There is also some evidence that dietary
trehalose can increase the virulence of C. difficile infections.23
Antifreeze (glyco)proteins (AF(G)P)s from polar fish provide
protection against ice formation and growth in hypothermal
conditions and have the most potent ice recrystallization inhibi-
tion (IRI) activity known.24 Synthetic IRI-active compounds
developed by Ben et al.25 have been shown to enhance cellular
recovery during cryopreservation.26 Gibson and co-workers have
developed synthetic polymers as mimetics of AF(G)Ps,27,28 which
have potent IRI activity and can be employed in solvent-free
cryopreservation.29–32 The most potent IRI-active polymer to date
is PVA (poly(vinyl alcohol)). PVA is a particularly appealing
additive as it is widely used in pharmaceutical formulations
and is an FDA approved food additive.33 Mitchell et al. found
that the reversible aggregation of gold nanoparticles during
freezing could be modulated by addition of PVA.34 By slowing
the rate of ice growth, the effective surface area of the ice crystals
is increased (i.e. more small crystals) and hence the nano-
particles could not approach each other to aggregate. We there-
fore hypothesized that IRI-active compounds might prevent
protein aggregation during ice-growth induced stress, which
normally leads to denaturation/deactivation. This effect could
in turn be exploited in the solvent-free storage proteins.
Results & discussion
The aim of this study was to investigate the utility of IRI-active
polymers as ‘polymer-only’ protein stabilizing agents for medi-
cally and biotechnologically important proteins. IRI activity was
studied using a modified splat assay. This showed that mean
length of ice crystals grown and held at sub-zero temperatures
(8 1C) in the presence of PVA are significantly smaller (%x = 15 mm)
than those grown without it (%x = 124 mm) (Fig. 1A). Smaller crystals
indicate more IRI-activity. In a normal frozen formulation any
proteins present would be phase separated to the surface of ice
crystals, producing a freeze concentrated liquid and an ice phase.
As the surface area of ice decreases, the proteins at the surface
should become more concentrated, and hence the likelihood of
aggregation will also increase. (Fig. 1B shows schematic of this
process).35 Here, we investigate the ability of IRI-active polymers
as non-covalent protein stabilizers to prevent these deleterious
eﬀects. An initial screen for cryoprotection/damage was conducted
using bacterial b-galactosidase (b-Gal).
b-Gal was frozen at 20 1C for 3 days in the presence of
trehalose (as a positive control), PVA or various polymers (HES,
PVP, PEG) which are known to have no IRI activity.28,29 Activity
was tested after thawing at 20 1C (Fig. 1D).
As expected, trehalose protected b-Gal activity during freezing.9
All other additives failed to protect when used individually,
apart from PEG which gave some protection (Fig. 1D). It should
be noted that PEG has known cryoprotectant properties at
suﬃciently high concentrations, making it the ideal choice
for a synergistic cryoprotectant.36 When PEG (100 mg mL1)
and PVA (1 mg mL1) were combined, a synergistic cryoprotec-
tive eﬀect was observed, reaching values equivalent to trehalose
(Fig. 1D). The combination of PEG/PVA appears to be unique
since PVP/PVA mixtures were no diﬀerent from individual
additives. Variable concentration studies (ESI†) show that the
PEG concentration could be lowered (at constant [PVA]) to as
low as 50 mg mL1 (B5 wt%) without aﬀecting recovery, but
below 30 mg mL1 there was no protection. We have previously
reported that a secondary water soluble polymer is required
when using IRI-active polymers for cellular cryopreservation,
agreeing with the observations here.29 PEG has widely been
found to have a stabilization eﬀect on various proteins, and is
used to improve delivery in pharmaceutical applications.37
Several studies suggest that PEG chains can interact with the
protein surface reducing solvent accessible area,38 and prevent
unfolding and aggregation through molecular crowding.39 These
stabilization eﬀects would also be useful in cryopreservation,
preventing aggregation caused by reduced liquid water volume
and any denaturing caused by low temperatures.
We hypothesised that the role of PVA in enhancing protein
cryostorage may be due to its IRI-activity. To test this hypo-
thesis, we tested another IRI-active polymer (p(ampholyte))
developed in our laboratory. Because p(ampholyte) is less IRI
active, we employed a higher concentration to achieve equal
IRI activity comparable to that of PVA at 1 mg mL1. Under
identical conditions, we found that p(ampholyte) and PVA
Fig. 1 Ice recrystallization inhibiting polymer mediated protein storage.
(A) Example ice crystal wafers grown with and without added PVA. Scale
bar – 100 mm; (B) Schematic showing protein aggregation (concentration)
changes as a function of ice crystal size; (C) polymers used in this study;
(D) recovery of b-Gal activity after freezing for 3 days at 20 1C, as % of
fresh, unfrozen protein. Error bars are S. D. from a minimum of 6 repeats,
** represents p o 0.01 relative to PBS buffer control. PEG, PVP, trehalose
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displayed identical cryoprotectant properties (Fig. 2A). This data
corroborates the hypothesis that ice growth is a cause of protein
deactivation and that the rational design of IRI-macromolecules
may be an eﬀective strategy for the discovery of new protein
stabilizers and be complementary to small molecular cryoprotec-
tants which function by diﬀerent mechanisms. To investigate if
preventing protein aggregation was a critical factor for protein
cryoprotection, we employed dynamic light scattering (DLS). When
b-Gal was freeze/thawed in phosphate-buﬀered saline (PBS) alone,
large aggregates could be seen (4500 nm in diameter) (Fig. 2B).
Similarly, large aggregates were also observed when only PVA
polymers were employed. Conversely, PEG/PVAmixtures prevented
all freeze-induced aggregation (Fig. 2B).
Our bio-inspired macromolecules have some advantages
over small-molecule cryoprotectants as they have low cyto-
toxicity, high biocompatibility (FDA approved/GRAS status for
several applications),33,40 and at equal mass concentrations
have lower molar concentration thus imposing less osmotic
stress. To confirm that our polymers are passive additives, we
incubated b-Gal with diﬀerent concentrations of cryoprotec-
tants and tested activity (Fig. 2C). Glycerol solutions signifi-
cantly impaired protein function or the assay output, but PEG,
PVA and trehalose had little impact on protein function, thus
indicating that they are biologically inert and may not need
removing before use, providing an alternative to solvent based
approaches, where dialysis is typically required post-thaw.
Since under standard laboratory conditions proteins are
normally stored at 80 1C through long periods, we decided
to test the levels of protein activity at this temperature. The
PEG/PVA formulation enabled recovery of b-Gal activity com-
parable to that of trehalose (Fig. 2D).
To ensure these observations were not unique to a single
enzyme we set out to study a range of other proteins using this
methodology. Glucose oxidase (GOx) is widely used in sensing,
food industry and in molecular biology41 whilst hyperthermo-
phylic DNA polymerase from Thermus aquaticus (Taq) is com-
monly used in diagnostics and research for the amplification of
DNA through the polymerase chain reaction (PCR) that under-
pins modern genomic analyses.42 We found that GOx was
relatively stable after freeze/thawing in only PBS, however, addi-
tion of IRI-active polymers did increase the recovered enzymatic
activity (Fig. 3A). To assess the activity of Taq after freeze/thawing,
we used quantitative PCR (qPCR) and determined the number of
cycles to reach a threshold level; fewer cycles means more activity.
We observed that PEG/PVA improved stability to the extent that it
was comparable to fresh recombinantly-expressed enzyme (Fig. 3B).
Encouraged by the above results we proceeded to more
closely reproduce laboratory or clinical settings where protein
samples are often removed and replaced from/into a freezer, a
freeze/thaw cycle assay was developed as a robust test of the
technology. To enable continual monitoring of the same sample
through many freeze/thaw cycles, recombinant green fluorescent
protein (GFP) was used. Upon denaturation, the fluorescence
decreases providing a convenient readout. Fig. 3C shows the
recovery of fluorescence following 6 freeze (20 1C) and thaw
(27 1C) cycles. For PEG alone, there was a dramatic reduction in
fluorescence with only 15% function retained after 6 cycles.
Addition of 1 mg mL1 PVA to PEG was found to be optimal,
enabling 475% activity retention after 6 freeze/thaw cycles.
Higher concentrations of PVA were found to be detrimental as
was the use of higher molecular weight PVA (23 kDa) (Fig. 3D).
Fig. 2 (A) Protein freeze/thaw recovery upon addition of p(ampholyte)
following b-Gal storage for 3 days at 20 1C, as % of fresh, unfrozen
protein. Concentrations as in Fig. 1, but p(ampholyte) used at 30 mg mL1.
(B) DLS analysis of b-Gal aggregation post freezing compared to fresh
protein (black line). (C) b-Gal activity after 1 hour incubation in the cryo-
storage solutions without freeze/thaw; (D) b-Gal recovery after 4 weeks
storage at 80 1C. Error bars are S. D. from minimum of 3 repeats.
Fig. 3 (A) Glucose oxidase recovery after 3 days storage at 20 1C;
(B) Taq polymerase activity recovery, after 3 days storage at 20 1C,
expressed as number of threshold cycles (lower is more active). ** repre-
sents p o 0.01 compared to control, error bars are from a minimum of
6 repeats. C + D show fluorescence recovery of GFP after freeze (20 1C)/
thaw (27 1C). All solutions containing 100 mg mL1 PEG plus PVA concen-
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We hypothesize that this is due to dynamic ice shaping – a
common side effect of antifreeze proteins, which is known to
compromise cell cryopreservation.32,43 This highlights the deli-
cate balance of IRI-activity with ice shaping and that the actual
polymer composition is crucial to success.
To determine if this methodology could be used for ther-
apeutic proteins as well as those described above, an antibody
(rabbit IgG) and insulin were both tested. Antibodies are widely
used in diagnostics (e.g. ELISA) and molecular biology as well as in
emerging therapeutics, but maintaining their function upon storage
is challenging. Rabbit IgG purified extract was stored at 20 1C for
3 days and function determined using an ELISA-based assay. As
with all the other proteins tested the PEG/PVA mixture greatly
enhanced IgG activity (480%) and the recovery level was superior
to that of trehalose (Fig. 4A). Insulin, a biologic therapeutic essential
for managing diabetes, is deactivated upon liquid storage by simple
agitation or by irreversible aggregation. Dynamic light scattering was
therefore employed to probe the prevention of irreversible insulin
aggregation upon freeze/thaw using a range of conditions (Fig. 4C).
Again the PEG/PVA formulation prevented aggregation more so
than PVA alone. Diﬀerent molecular weight PEGs were considered,
4 kDa and 2 kDa, showing that 4 kDa PEG specifically, in combi-
nation with PVA protects insulin from aggregation and thus inacti-
vity. This implies certain molecular weights are important for a
solvent-free, polymer only cryopreservation formulation.
Conclusions
In conclusion, we show that bio-inspired ice-recrystallization
inhibiting polymers present a materials-chemistry solution to
therapeutic protein storage, as an alternative to the traditional
solvent-based approach. The formulation is shown to match
the performance of trehalose, and oﬀers some advantages over
glycerol storage. The mechanism of action appears to be pre-
vention of irreversible aggregation, with a secondary hydro-
philic polymer (PEG) being essential, which is distinct from
how small molecule cryoprotectants function. This is advanta-
geous over current solvent based techniques, but also as an
alternative to emerging covalent polymer–protein conjugation
approaches. Our additives, PEG and PVA, are widely used
in pharmaceutical products, are available as clinical-grade
materials, are biocompatible and non-immunogenic, and are
compatible with current biologics, with no additional bio-
conjugation being required. These antifreeze protein-inspired
polymers may be useful tools for protein storage in both
biotechnology research and healthcare.
Experimental
Protein freezing
Samples were made in triplicate at the appropriate concentra-
tions and frozen in 1.5 mL eppendorf tubes by directly placing
in a freezer either at 20 1C or 80 1C. The samples were then
held at this temperature for the indicated time period and then
thawed at 20 1C.
b-Gal activity
Determined by a colorimetric assay involving the use of
o-nitrophenyl-b-D-galactoside (ONPG). Briefly aliquots of
30 mL of 4 mg mL1 ONPG were added to wells of a 96 well
plate containing 50 mL of 20 mg mL1 b-Gal solution. This was
then incubated at room temperature for 5 minutes and
quenched by addition of 50 mL of 1 M Na2CO3 solution.
Absorbance was measured at 420 nm. All other methods are
in the ESI.†
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Fig. 4 (A) Rabbit IgG activity recovered after 3 days storage at 20 1C
relative to fresh antibody in a surface binding assay. ** represents po 0.01,
error bars are from a minimum of 6 repeats; (B) schematic showing ease of
freezing methodology; (C) DLS curves of insulin before (solid) and after
(dashed) 12 freeze/thaw cycles. Black = insulin only, Red = insulin + PVA,
Green = +2 kDa PEG + PVA, Blue = + 4 kDa PEG + PVA. IN all cases
PEG = 100 mg mL1 and PVA =1 mg mL1. (D) Average size of insulin
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